GlassScriptPhysician profile
Holly Johnson
NPI 1073049995
$1,836.34
in general payments reported to CMS, 2019-2025
21 companies · $89.00 in 2025
The $89.00 reported for 2025 was less than what a typical Women'S Health (Nurse Practitioner) provider received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $381 · 2022: $660 · 2023: $481 · 2024: $224 · 2025: $89.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $695 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $694.89 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novastep INC. | $370.03 | 2022 | |
| Pfizer INC. | $215.17 | 2021-2024 | |
| Daiichi Sankyo INC. | $190.01 | 2021-2023 | Injectafer |
| Organon LLC | $155.64 | 2021-2025 | Nexplanon |
| Myriad Women'S Health, INC. | $137.32 | 2023 | Myrisk |
| Evofem Biosciences, INC. | $135.95 | 2021-2024 | Phexxi |
| Astellas Pharma US INC | $132.91 | 2023-2024 | Veozah |
| Abbvie INC. | $89.76 | 2021-2025 | |
| Hologic Sales and Service, LLC | $71.91 | 2021-2024 | Myosure Tissue Removal Device, Novasure |
| Smith+Nephew, INC. | $60.51 | 2021-2023 | Stravix Pl, Stravix |
| Lilly USA, LLC | $52.48 | 2025 | Zepbound, Mounjaro |
| Lupin INC. | $50.00 | 2021 | |
| Exeltis, USA INC. | $31.81 | 2021-2023 | Slynd |
| Pacira Pharmaceuticals Incorporated | $28.47 | 2021-2022 | |
| Avion Pharmaceuticals | $28.19 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $16.62 | 2023 | |
| Novo Nordisk INC | $16.34 | 2023 | Wegovy |
| Therapeuticsmd, INC. | $14.57 | 2021 | |
| Alexion Pharmaceuticals, INC. | $13.84 | 2023 | Ultomiris |
| Shield Therapeutics INC | $13.68 | 2024 | |
| Merck Sharp & Dohme LLC | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.